Renal Denervation: Device Market’s Gold Rush
This article was originally published in Start Up
Three years ago, only Ardian was publicly working on renal denervation devices for hypertension, but at last month’s ACC meeting, some said there were now anywhere from 16 to 40 companies in the space. Fast followers don’t want to miss out on an IP land grab in today’s hottest medical device space.
You may also be interested in...
Device/Diagnostics Quarterly Deal Statistics, Q4 2012
Device firms closed the final quarter of 2012 with $1.1 billion in financing, led by Volcano’s debt offering. Takeovers of Gambro and PSS Medical topped the device M&A list. At $196 million, Q4 diagnostic financing was the lowest quarter of the year, but IPOs returned with three public debuts. Amgen’s $415 million acquisition of deCODE was the largest diagnostic M&A.
Renal Denervation Land Grab Continues As Boston Scientific Buys Vessix
In the latest of a series of deals in what many industry executives and analysts consider to be the next blockbuster device product market, Boston Scientific became the third major vascular player to buy its way into the renal denervation space with its recent acquisition of Vessix Vascular for a sum that could amount to $425 million. With this deal, Boston Scientific joins Medtronic, which led the way in 2010 with its stunning potentially billion dollar acquisition of Ardian, followed earlier this year by Covidien’s acquisition of Maya Medical.
The Renal Denervation Buzz: Separating Fact From Myth
Is renal denervation the next blockbuster device technology? Judging by the excitement at the EuroPCR meeting in May, the potential is there. Just before the meeting, Covidien announced its acquisition of renal denervation start-up Maya Medical.